TGFB2 and hereditary clear cell renal cell carcinoma: Fresolimumab (GC1008) is a monoclonal IgG4 antibody designed to reduce effector immune cell function through the neutralization of TGF-β1, TGF-β2, and TGF-β3, it was clinically investigated as monotherapy or in combination with radiotherapy in renal cell carcinoma, pleural mesothelioma, NSCLC, metastatic breast cancer and glioma phase I and II clinical trials in which it showed promising antitumor activities with minimal toxicities [124].